Psychosocial Department, Emma Children's Hospital AMC, University of Amsterdam, Amsterdam, The Netherlands.
J Dev Behav Pediatr. 2012 Oct;33(8):633-40. doi: 10.1097/DBP.0b013e3182690727.
The Dutch neonatal congenital hypothyroidism (CH) screening procedure and treatment modality has been adapted several times since its national institution in 1981. These changes enabled us to investigate whether earlier treatment has resulted in improved cognitive and motor outcomes. The present study examined whether the advancement of treatment modality has resulted in improved cognitive and motor outcomes.
In 95 toddlers with thyroidal CH (CH-T), born in 2002 through 2004 and treated at a median age of 9 days, cognitive and motor outcomes were assessed with the Bayley Scales of Infant Development-II-NL at 1 and 2 years of age. This outcome was also analyzed in relation to treatment variables.
The mean mental developmental index (MDI) scores of the severe (initial free thyroxine [FT4] ≤0.4 ng/dL (≤5 pmol/L), moderate (0.4 < initial FT4 ≤ 0.8 ng/dL (5.0 < initial FT4 ≤ 10.0 pmol/L), and mild (initial FT4 > 0.8 ng/dL (>10.0 pmol/l) CH-T groups at 1 year and the moderate and mild CH-T groups at 2 years were similar to the population mean. The mean MDI scores of the total CH-T group and severe CH-T group at 2 years were significantly lower than the population mean (p < .0001). In all 3 severity subgroups, significant lower psychomotor developmental index scores (p < .0001) were observed. No correlations were found between starting day of treatment and developmental outcome. Initial T4 concentration and initial T4 dose were weak predictors for developmental outcome.
Essentially, comparable with our earlier findings, children with CH, especially those with severe CH, are still at risk for motor and cognitive problems, which are probably due to the consequence of the prenatal hypothyroid state or the thyroid hormone deficiency in early life.
自 1981 年在荷兰开展新生儿先天性甲状腺功能减退症(CH)筛查以来,其筛查程序和治疗方式已几经调整。这些变化使我们能够研究更早的治疗是否会改善认知和运动结果。本研究旨在探讨治疗方式的改进是否改善了认知和运动结果。
在 2002 年至 2004 年期间出生的 95 名甲状腺性 CH(CH-T)婴儿中,选取治疗中位年龄为 9 天的 95 名婴儿,在 1 岁和 2 岁时使用贝利婴幼儿发育量表第二版-荷兰语版(Bayley Scales of Infant Development-II-NL)评估认知和运动结果。还分析了这些结果与治疗变量的关系。
1 岁时,严重(初始游离甲状腺素[FT4]≤0.4ng/dL(≤5pmol/L)、中度(0.4<初始 FT4≤0.8ng/dL(5.0<初始 FT4≤10.0pmol/L)和轻度(初始 FT4>0.8ng/dL(>10.0pmol/L)CH-T 组的平均精神发育指数(MDI)评分与人群均值相似。2 岁时,中度和轻度 CH-T 组的平均 MDI 评分与人群均值相似。但总 CH-T 组和严重 CH-T 组的平均 MDI 评分均显著低于人群均值(p<0.0001)。在所有 3 个严重程度亚组中,均观察到精神运动发育指数评分显著降低(p<0.0001)。起始治疗日与发育结果之间无相关性。初始 T4 浓度和初始 T4 剂量是发育结果的弱预测因素。
与我们之前的发现基本一致,CH 患儿,尤其是严重 CH 患儿,仍然存在运动和认知问题的风险,这可能是由于产前甲状腺功能减退状态或生命早期甲状腺激素缺乏的后果所致。